research Computational Screening of Repurposed Drugs Targeting Sars-Cov-2 Main Protease By Molecular Docking
Danoprevir, remdesivir, and saridegib may effectively inhibit SARS-CoV-2.
Search
for
Sort by
Research
30-60 / 1000+ results research Acute inflammatory demyelinating polyneuropathy associated with pegylated interferon α 2a therapy for chronic hepatitis C virus infection
Pegylated interferon-alpha 2a can cause a rare nerve disorder, but early treatment can lead to full recovery.
research Alopecia induced by lopinavir plus ritonavir therapy in an HIV patient.
An HIV patient's complete hair loss was reversed after switching from lopinavir/ritonavir to nelfinavir.
research Taming of Covid-19: potential and emerging application of mesenchymal stem cells
Mesenchymal stem cells show promise in treating COVID-19 by reducing inflammation and aiding recovery, but more research is needed.
research Pegylated-interferon-α2ain clinical practice: how to manage patients suffering from side effects
Manage side effects of hepatitis C treatment with dose changes and medications, which may improve patient adherence and treatment success.
research The antiviral activity of a small molecule drug targeting the NSP1-ribosome complex against Omicron, especially in elderly patients
Golvatinib shows promise as a treatment for Omicron in elderly patients.
research Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods
Five FDA-approved drugs may help block COVID-19 virus entry.
research Antiviral Drugs Screening for Swine Acute Diarrhea Syndrome Coronavirus
Five existing drugs may help fight Swine Acute Diarrhea Syndrome Coronavirus.
research Repurposing of Drugs as Novel Influenza Inhibitors From Clinical Gene Expression Infection Signatures
A blood pressure drug, diltiazem, may also help treat influenza.
research Vogt-Koyanagi-Harada disease occurring during pegylated interferon-α2b and ribavirin combination therapy for chronic hepatitis C
Vogt-Koyanagi-Harada disease can develop during interferon therapy for chronic hepatitis C.
research Drug interactions between common dermatological medications and the oral anti-COVID-19 agents nirmatrelvir-ritonavir and molnupiravir
Some skin medications can have harmful interactions with the COVID-19 drug nirmatrelvir-ritonavir, but not with molnupiravir.
research A skin organoid-based infection platform identifies an inhibitor specific for HFMD
NSC167409 can effectively inhibit the virus causing hand, foot, and mouth disease.
research Hair Loss Induced by Lopinavir-Ritonavir
The medication lopinavir-ritonavir may cause severe hair loss.
research Docking-based workflow and ADME prediction of some compounds in Curcuma longa and Andrographis paniculata as polymerase PA-PB1 inhibitors of influenza A/H5N1 virus
Compounds from turmeric and bitter show strong potential as antiviral agents against the influenza A virus.
research Irreversible alopecia universalis during treatment with pegylated interferon-ribavirin for chronic hepatitis C virus infection: Case report and published work review
A man lost all his hair permanently after hepatitis C treatment, a side effect not seen before.
research Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: expert opinion
Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.
research A Real‐World Disproportionality Analysis of Avacopan in Anti‐Neutrophil Cytoplasmic Antibodies Associated Vasculitis: Insights From FDA Adverse Event Reporting System
Avacopan may cause unexpected side effects, so early monitoring is important.
research Segmental Vitiligo and Hair Curling After Interferon α and Ribavirin Treatment for Hepatitis C
A woman developed white patches on her skin and curly hair after hepatitis C treatment, likely due to the medication interferon alpha.
research Osteosclerosis and periostal new bone formation during indinavir therapy
Indinavir, especially with vitamin A, may cause bone changes, but switching to nelfinavir can reduce these effects.
research Virtual Screening of Potential Inhibitors for SARS-CoV-2 Main Protease
The document concluded that certain compounds might strongly bind to and potentially inhibit a key SARS-CoV-2 protein, but further testing is needed.
research Bibliometric analysis and visualization of research trends on HIV-1 capsid inhibitors (2000–2022)
Research on HIV-1 capsid inhibitors has progressed significantly, with the U.S. leading in contributions.
research Cepharanthine: A review of the antiviral potential of a Japanese-approved alopecia drug in COVID-19
Cepharanthine could be a strong antiviral against COVID-19.
research A Review of Adverse Cutaneous Drug Reactions Resulting from the Use of Interferon and Ribavirin
Interferon and ribavirin can cause serious skin reactions and other health issues.
research Nail, hair and skin hyperpigmentation associated with indinavir therapy
Indinavir therapy can cause reversible skin, hair, and nail darkening.
research [Study of gonadal hormone drugs in blocking filovirus entry of cells in vitro].
Some gonadal hormone drugs can block filovirus entry into cells.
research Advances in nucleoside monophosphate prodrugs as anti-HCV agents
New treatments for Hepatitis C show promise but need more research to confirm their safety and effectiveness for clinical use.
research Molecular Mechanism of Avicennia marina (Forssk.) Vierh. in Inhibiting Hepatitis C Virus Based on Network Pharmacology and Molecular Docking
Avicennia marina shows potential to treat Hepatitis C by targeting key proteins.
research The efficacy and particular side effects of therapy peginterferon alpha-2a acute hepatitis C hemodialysed patients
Peginterferon alpha-2a effectively treats acute hepatitis C in hemodialysed patients, despite some side effects.
research Reversible Alopecia Universalis During Treatment with PEG-Interferon and Ribavirin for Chronic Hepatitis C
Some patients may experience temporary total hair loss from hepatitis C treatment with PEG-interferon and ribavirin.
research Alopecia universalis as a side effect of pegylated interferon α-ribavirin combination therapy for hepatitis C: a rare case report
A man lost all his hair as a rare side effect after hepatitis C treatment.